Digital Biomarkers Market is Set to Witness Significant Growth of 35% during 2021 to 2026

1
Digital Biomarkers Market Growth Opportunity by
Top Key Players ActiGraph, LLC (US), AliveCor
Inc. (US), Amgen Inc. (US), Biogen Inc. (US)
2
Digital biomarkers are indexes that use data from
digital platforms such as smartphones and
wearable devices to objectively visualize the
presence or absence of a disease, as well as
changes caused by treatment. Advanced analytics
and artificial intelligence (AI) algorithms are
used by digital biomarkers to analyze data in
ways that are not possible for humans to do
alone. The Global Digital Biomarkers Market is
set to witness a significant CAGR of 35 from
2021 to 2026. Some of the important drivers
propelling the global digital biomarkers market
are high investments in RD, increasing usage of
digital tools such as smartphones and wearables,
development of novel products by market players,
high cost involved in drug development, and
rising demand for mobile health apps. High
investments and funding to grow novel
technologies to fuel its high demand Future
treatments and diagnostic protocols for certain
indications, including cancer, amyotrophic
lateral sclerosis (ALS), and Alzheimer's disease,
are expected to rely heavily on digital
biomarkers. High growth of the digital biomarkers
market has led to a number of investments and
funding activities to accelerate research on
digital biomarkers.
3

• Some of these are listed below
• In May 2022, Imagene AI, an Israel based digital
  biomarker company, secured US 21.5 million
  funding that includes US 3 million in seed
  funding led by Blumberg Capital and Series A
  round of US 18.5 million led by
  technology-driven cancer medicine investors, to
  focus on precision medicine in cancer care
• In February 2022, Koneksa, a company engaged in
  designing and validating digital biomarkers
  raised US 45 million Series C Financing led by
  AyurMaya, joined by Takeda Ventures and Velosity
  Capital, and existing investors such as McKesson
  Ventures, Merck Global Health Innovation Fund,
  Novartis, and others, to accelerate the expansion
  of digital biomarker platform
• In August 2021, the Alzheimers Drug Discovery
  Foundation (ADDF), US, awarded a funding up to
  US 2 million to the Early Detection of
  Neurodegenerative diseases (EDoN) initiative for
  a joint research programme led by Alzheimer's
  Research UK, with the goal of developing a
  digital biomarker to identify Alzheimer's disease
  at its earliest stage
• Explore Premium Report on Digital Biomarkers
  Market _at_ https//meditechinsights.com/digital-biom
  arkers-market/

4

• Big pharma companies and government bodies extend
  focus on digital biomarkers to boost the
  acceptance of digital biomarkers market
• Digital biomarkers are much more than fitness
  trackers and smartwatches. The digital biomarkers
  market has witnessed a number of big pharma
  companies partnering with innovative digital
  health start-ups to improve the acceptance of
  this technology and co-develop advanced
  solutions. With the massive burden caused by
  Covid-19 pandemic, government bodies have also
  shown interest for the development of digital
  biomarker based therapeutic solution.
• The following is a list of some recent advances
  in this area
• In March 2022, AstraZeneca partnered with Huma
  Therapeutics, a UK-based medical technology
  company, to develop Software as a Medical Device
  (SaMD) companion apps for several therapeutic
  conditions by combining predictive algorithms,
  digital biomarkers, and real-world data
• In January 2021, Biogen announced its partnership
  with Apple for the development of cognitive
  health digital biomarkers by assessing the
  potential of iPhone and Apple Watch for
  conditions such as mild cognitive impairment
  (MCI)
• In September 2020, National Institute of Health
  (NIH) awarded a contract to physIQ, a company
  that bring life-saving therapies to market
  faster. This contract is aimed at developing an
  innovative AI-based COVID-19 digital biomarker
  solution

5
Competitive Landscape Analysis of Digital
Biomarkers Market The global digital biomarkers
market is marked by the presence of key players
such as ActiGraph, LLC (US), AliveCor Inc. (US),
Amgen Inc. (US), Biogen Inc. (US), AiCure (US),
AstraZeneca (UK), and others. For More Detailed
Insights, Contact Us _at_ https//meditechinsights.co
m/contact-us/ About Medi-Tech Insights Medi-Tech
Insights is a healthcare-focused business
research insights firm. Our clients include
Fortune 500 companies, blue-chip investors
hyper-growth start-ups. We have completed 100
projects in Digital Health, Healthcare IT,
Medical Technology, Medical Devices Pharma
Services. Contact Ruta Halde Associate,
Medi-Tech Insights 32 498 86 80
79 info_at_meditechinsights.com